An experimental therapy for bladder cancer is predicted to soon be entering Phase I clinical trials in the UK following a development pact signed between Cancer Research UK, its commercial arm Cancer Research Technology, and Sitka Biopharma, a Canadian biotech. Sitka’s therapy (STK-01) is being developed to improve delivery of chemotherapy in non-muscle invasive bladder
Cancer Research UK have funded a trial that allows GP surgeries to test for Barrett’s Oesophagus, a condition which can increase the chances of developing oesophageal cancer. Up to 150 GP practices nationwide will trial offering the Cytosponge test, a less invasive way to test for changing oesophageal cells in patients experiencing acid reflux symptoms.
BioInvent International have announced that they have signed a clinical trial partnership with Cancer Research UK, Cancer Research Technology, and with Leukaemia and Lymphoma Research. The clinical trial partnership will assess BioInvent’s experimental antibody, BI-1206, in reducing resistance to rituximab treatment in patients with certain blood cancers.